These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26020027)

  • 1. Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation.
    Teng W; Liu KW; Lin CC; Jeng WJ; Chen WT; Sheen IS; Lin CY; Lin SM
    Liver Cancer; 2015 Mar; 4(1):26-38. PubMed ID: 26020027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Local Tumor Progression after Radiofrequency Ablation (RFA) of Hepatocellular Carcinoma by Assessment of Ablative Margin Using Pre-RFA MRI and Post-RFA CT Registration.
    Yoon JH; Lee JM; Klotz E; Woo H; Yu MH; Joo I; Lee ES; Han JK
    Korean J Radiol; 2018; 19(6):1053-1065. PubMed ID: 30386137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion.
    Kim YS; Lee WJ; Rhim H; Lim HK; Choi D; Lee JY
    AJR Am J Roentgenol; 2010 Sep; 195(3):758-65. PubMed ID: 20729457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ablative safety margin depicted by fusion imaging with post-treatment contrast-enhanced ultrasound and pre-treatment CECT/CEMRI after radiofrequency ablation for liver cancers.
    Bo XW; Xu HX; Guo LH; Sun LP; Li XL; Zhao CK; He YP; Liu BJ; Li DD; Zhang K; Wang D
    Br J Radiol; 2017 Oct; 90(1078):20170063. PubMed ID: 28749166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of computed tomography fusion imaging for the evaluation of the ablative margin of radiofrequency ablation for hepatocellular carcinoma and the correlation to local tumor progression.
    Makino Y; Imai Y; Igura T; Hori M; Fukuda K; Sawai Y; Kogita S; Ohama H; Matsumoto Y; Nakahara M; Zushi S; Kurokawa M; Isotani K; Takamura M; Fujita N; Murakami T
    Hepatol Res; 2013 Sep; 43(9):950-8. PubMed ID: 23356912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy and Therapeutic Outcome of Bipolar Radiofrequency Ablation for the Treatment for Hepatocellular Carcinoma in the Real-World Setting, Compared with Monopolar Radiofrequency Ablation Conducted during the Same Period.
    Tanaka T; Takata K; Kunimoto H; Fukuda H; Yamauchi R; Tsuchiya N; Inomata S; Yokoyama K; Morihara D; Takeyama Y; Shakado S; Sakisaka S; Hirai F
    Oncology; 2020; 98(12):859-868. PubMed ID: 32799203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal ablative margin (MAM) assessment with image fusion: an independent predictor for local tumor progression in hepatocellular carcinoma after stereotactic radiofrequency ablation.
    Laimer G; Schullian P; Jaschke N; Putzer D; Eberle G; Alzaga A; Odisio B; Bale R
    Eur Radiol; 2020 May; 30(5):2463-2472. PubMed ID: 32002642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of Nonrigid Registration of Pre-Procedure MR with Post-Procedure CT After Radiofrequency Ablation for Hepatocellular Carcinoma.
    Park J; Lee JM; Lee DH; Joo I; Yoon JH; Park JY; Klotz E
    Cardiovasc Intervent Radiol; 2017 Jun; 40(6):873-883. PubMed ID: 28091728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of fused imaging for the evaluation of radiofrequency ablative margin for hepatocellular carcinoma.
    Tomonari A; Tsuji K; Yamazaki H; Aoki H; Kang JH; Kodama Y; Sakurai Y; Maguchi H
    Hepatol Res; 2013 Jul; 43(7):728-34. PubMed ID: 23198863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome.
    Zytoon AA; Ishii H; Murakami K; El-Kholy MR; Furuse J; El-Dorry A; El-Malah A
    Jpn J Clin Oncol; 2007 Sep; 37(9):658-72. PubMed ID: 17766723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors, Patterns, and Long-Term Survival of Recurrence After Radiofrequency Ablation With or Without Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Huang J; Huang W; Guo Y; Cai M; Zhou J; Lin L; Zhu K
    Front Oncol; 2021; 11():638428. PubMed ID: 34123790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma.
    Hao Y; Numata K; Ishii T; Fukuda H; Maeda S; Nakano M; Tanaka K
    World J Gastroenterol; 2017 May; 23(17):3111-3121. PubMed ID: 28533668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central lower attenuating lesion in the ablation zone on immediate follow-up CT after percutaneous radiofrequency ablation for hepatocellular carcinoma: incidence and clinical significance.
    Park Y; Choi D; Rhim H; Kim YS; Lee JY; Chang I; Lim HK; Park CK
    Eur J Radiol; 2010 Sep; 75(3):391-6. PubMed ID: 19467813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety margin after radiofrequency ablation of hepatocellular carcinoma: precise assessment with a three-dimensional reconstruction technique using CT imaging.
    Jiang C; Liu B; Chen S; Peng Z; Xie X; Kuang M
    Int J Hyperthermia; 2018 Dec; 34(8):1135-1141. PubMed ID: 29392978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of Extracted-Overlay Fusion Imaging for Intraoperative Treatment Evaluation of Radiofrequency Ablation for Hepatocellular Carcinoma.
    Makino Y; Imai Y; Igura T; Kogita S; Sawai Y; Fukuda K; Iwamoto T; Okabe J; Takamura M; Fujita N; Hori M; Takehara T; Kudo M; Murakami T
    Liver Cancer; 2016 Oct; 5(4):269-279. PubMed ID: 27781199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-dimensional contrast-enhanced ultrasound fusion imaging predicts local tumor progression by evaluating ablative margin of radiofrequency ablation for hepatocellular carcinoma: a preliminary report.
    Ye J; Huang G; Zhang X; Xu M; Zhou X; Lin M; Xie X; Xie X
    Int J Hyperthermia; 2019; 36(1):55-64. PubMed ID: 30444428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ablation margin assessment of liver tumors with intravenous contrast-enhanced C-arm computed tomography.
    Iwazawa J; Ohue S; Hashimoto N; Mitani T
    World J Radiol; 2012 Mar; 4(3):109-14. PubMed ID: 22468192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postablation assessment using follow-up registration of CT images before and after radiofrequency ablation (RFA): prospective evaluation of midterm therapeutic results of RFA for hepatocellular carcinoma.
    Shin S; Lee JM; Kim KW; Joo I; Han JK; Choi BI; Klotz E
    AJR Am J Roentgenol; 2014 Jul; 203(1):70-7. PubMed ID: 24951197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronal reformatted CT images contribute to the precise evaluation of the radiofrequency ablative margin for hepatocellular carcinoma.
    Motoyama T; Ogasawara S; Chiba T; Higashide T; Yokota H; Kanogawa N; Suzuki E; Ooka Y; Tawada A; Irie R; Ochi S; Masuda Y; Uno T; Yokosuka O
    Abdom Imaging; 2014 Apr; 39(2):262-8. PubMed ID: 24346490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of ablative margin by MRI with ferucarbotran in radiofrequency ablation for liver cancer: comparison with enhanced CT.
    Tokunaga S; Koda M; Matono T; Sugihara T; Nagahara T; Ueki M; Murawaki Y; Kakite S; Yamashita E
    Br J Radiol; 2012 Jun; 85(1014):745-52. PubMed ID: 21385915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.